Impax has another recall tied to labeling issue

Impax Laboratories has again been tripped up by labeling issues on a drug and is retrieving a lot of a med for treating epilepsy or bipolar disorders in its most recent recall.

The Hayward, CA-based drugmaker has issued a recall for one lot of lamotrigine orally disintegrating tablets in the 200 mg dose because the blister packs might contain 100 mg tablets instead, which means patients might not get their full dose.

Impax ($IPXL) said in a recall letter that each blister card within the unit-of-use blister pack is properly labeled as 100 mg ODT, but that the plastic shell pack containing the 100 mg blister cards is labeled as 200 mg ODT. It said shell packs from the affected lot may contain 100 mg tablets instead of 200 mg tablets.

Conference

The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

This is the second recall in recent months that Impax has made because of labeling issues. The earlier recall was for 21 lots, affecting more than 35 million capsules of fenofibrate, a drug to help lower high cholesterol and triglycerides in the blood. In that recall, the FDA reported that the packages might have incorrect or missing lot numbers or expiration dates.

- here’s the release

Related Article: 
Impax, AmerisourceBergen unit recall more than 35M fenofibrate capsules

Suggested Articles

Novartis' AveXis will use Catalent for some manufacturing of its newly approved gene therapy Zolgensma and more manufacturing news of note.

Pharmacy chain Rite Aid has partnered with Google to have their drug recycling stations easily searchable on Google Maps. 

Precision BioSciences says it will have a manufacturing facility for its off-the-shelf CAR-T therapies up and running in the fourth quarter.